Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

year 2012.  Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 21648922.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering conference ID# 21648922.  The webcast will remain available on the company's website until the next earnings call.

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, the company is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment a
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... May 21, 2013  The Lindsley F. Kimball Research Institute ... is a Grand Challenges Explorations winner, an initiative ... Dr. Sara Lustigman , Head of the ... and development research project, titled Innovative 3-D in ... are needed to screen drugs to help eliminate onchocerciasis (river ...
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2
... Augments Senior Management Team with Recent Strategic Hires ... ... May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced that ... for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia Consortium, ...
... Executive Chairman Set Sights on Expanding,Therapeutic Horizons of ... BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May ... joined Fate Therapeutics as,president and CEO and executive ... internationally recognized stem cell scientists,clinicians and investors dedicated ...
... 14 Campbell Alliance,the leading management consulting firm ... that Gary Tyson, Senior Vice,President of the firm,s ... the global rollout of electronic data capture (EDC),systems ... will be,held on May 28-29, 2008, at the ...
Cached Biology Technology:Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 2Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 3Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 4Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 5Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team 6Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe 2Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe 3
(Date:5/21/2013)... world,s largest scientific society, invites news media coverage ... 8-12, 2013, in Indianapolis, Ind. It will take ... area hotels. , With more than 7,100 presentations ... from astronomy to zoology ― the meeting will ... assortment of spot news and feature possibilities. The ...
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... book designed for parents helps them better understand the ... fight them, while offering practical advice for preventing infections ... Your Kids: The Complete Guide to Protecting (without Overprotecting) ... Press, is the inside source on germ defense ...
... proteins have finally explained why computer models of proteins ... This work could have vast implications in bioengineering and ... between structure and function in these basic building blocks ... as the cover article of the Oct. 16 issue ...
... average price for all types of gasoline is holding ... at the pump might be short-lived as research from ... biggest hurdles to the wide-scale production of fuel cell-powered ... biomolecular engineering, led the research team in discovering a ...
Cached Biology News:Handbook helps parents deal with childhood infections 2Speed plays crucial role in breaking protein's H-bonds 2Speed plays crucial role in breaking protein's H-bonds 3Fuel cells gearing up to power auto industry 2Fuel cells gearing up to power auto industry 3
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known virus microRNAs ...
...
... is an excellent choice for supporting hydrocarbon processing. ... GC, this one-channel workhorse can double sample throughput ... one. You get all the capability and reliability ... instrument that has the same proven performance of ...
... GC-8A is Shimadzu's basic gas chromatograph model ... use, the GC-8A supports a single detector, ... injection port(s), and analog output. Isothermal or ... The GC-8A is only 17.3 inches (43.9 ...
Biology Products: